Euthasol 40% Solution for Injection

Main information

  • Trade name:
  • Euthasol 40% Solution for Injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Euthasol 40% Solution for Injection
    Italy
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Pentobarbital
  • Therapeutic area:
  • Cats, Cattle, Dogs, Horses, Other, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0370/001
  • Authorization date:
  • 28-09-2011
  • EU code:
  • UK/V/0370/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2011

AN:00665/2010

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Euthasolvet.400mg/ml,solutionforinjection(AT,BE,EE,EL,FI,IE,IS,LT,LU,LV,

NO,PL,SE,UK)

Euthasol400mg/ml,solutionforinjection(ES,PT)

Euthasolvet.solutionforinjection(FR)

Euthasolvet.400mg/mlsolutionforinjectionfordogs,cats,rodents,rabbits,cattle,

sheep,goats,horsesandmink(IT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Perml:

Activesubstance:

Pentobarbital(assodiumsalt) 362.9mg

(equivalentto400mgpentobarbitalsodium)

Excipient(s):

Benzylalcohol(E1519) 20mg

PatentBlueV(E131) 0.01mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clearblueliquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs,cats,rodents,rabbits,cattle,sheep,goats,horsesandmink.

4.2 Indicationsforuse,specifyingthetargetspecies

Euthanasia

4.3 Contraindications

Donotuseforanaesthesia.

Issued:December2011

AN:00665/2010

Page2of6

4.4Specialwarningsforeachtargetspecies

-Intravenousinjectionofpentobarbitalhastheabilitytocauseinductionexcitement

inseveralspeciesofanimalandadequatesedationshouldbeappliedifdeemed

necessarybytheveterinarysurgeon.Measuresshouldbetakentoavoid

perivascularadministration(e.g.byusingintravenouscatheter).

-Theintraperitonealrouteofadministrationmaycauseaprolongedonsetofaction

withanincreasedriskofinductionexcitement.Intraperitonealadministrationmust

onlybeusedfollowingappropriatesedation.Measuresshouldbetakentoavoid

administrationintothespleenororgans/tissuewithlowcapacityforabsorption.This

routeofadministrationisonlysuitableforsmallanimals.

-Intracardiacinjectionmustonlybeusediftheanimalisheavilysedated,

unconscious,oranesthetized.

Toreducetheriskofinductionexcitement,euthanasiashouldbeperformedinaquiet

area.

Inhorsesandcattle,premedicationwithanappropriatesedativemustbeusedto

produceprofoundsedationbeforeeuthanasiaandanalternativemethodof

euthanasiashouldbeavailable.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

-Theintravenousrouteofadministrationshouldbetherouteofchoiceandadequate

sedationshouldbeappliedifdeemednecessarybytheveterinarysurgeon.For

horsesandcattlepremedicationismandatory.

Whereintravenousadministrationisimpossible,andonlyfollowingdeepsedation,

theproductmaybeadministeredviatheintracardiacrouteinallnamedspecies.

Alternatively,forsmallanimalsonly,administrationviatheintraperitonealroutecould

beused,followingappropriatesedation.

-Intheeventofaccidentaladministrationtoananimalnotpresentedforeuthanasia,

measuressuchasartificialrespiration,administrationofoxygenandtheuseof

analepticsareappropriate.

-Ingestionofeuthanasedanimalsbyotheranimalsmayleadtointoxication,

anaesthesiaandevendeath.Barbituratesarealsohighlystabletocooking

temperature.Duetotheriskofsecondaryintoxicationanimalseuthanasedwiththe

veterinarymedicinalproductshouldnotbefedtootheranimalsbutshouldbe

disposedofinaccordancewithnationallegislationandinamannerthatother

animalscannothaveaccesstothecarcasses.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Pentobarbitalisapotenthypnoticandasedative,andthuspotentiallytoxicinman.It

canbeabsorbedsystemicallythroughtheskinandifswallowed.Particularcare

shouldbetakentoavoidaccidentalingestionandself-injection.

Issued:December2011

AN:00665/2010

Page3of6

Incaseofaccidentalself-injection,ingestionorspillageontoskinorintoeyes,seek

medicaladviceimmediatelyandshowthepackageleafletorthelabeltothe

physician.DONOTdriveassedationmayoccur.

Incaseofaccidentalself-injection,obtainURGENTmedicalattention,advising

medicalservicesofbarbituratepoisoning.

Incaseofspillageontoskin,washtheexposedskinimmediatelyafterexposurewith

largeamountofwater.

Incaseofcontactwitheyes,rinseimmediatelywithplentyoffreshwaterandobtain

medicaladvice.

Incaseofingestion,washoutmouthandobtainmedicalattentionimmediately.

Impermeableprotectiveglovesshouldbewornwhenhandlingthisproduct.

Peoplewithknownhypersensitivitytopentobarbitalshouldavoidcontactwiththe

veterinarymedicinalproductoradministertheproductwithcaution.

AdvicetoDoctor:Theconcentrationofpentobarbitalintheproductissuchthatthe

accidentalinjectionoringestionofquantitiesassmallas1mlinhumanadultscan

haveseriousCNSeffects.Adoseofpentobarbitalsodiumof1g(equivalentto2.5ml

ofproduct)hasbeenreportedtobefatalinhumans.Treatmentshouldbesupportive

withappropriateintensivetherapyandmaintainingtherespiration.

4.6Adversereactions(frequencyandseriousness)

Minormuscletwitchingmayoccurafterinjection.

Deathmaybedelayediftheinjectionisadministeredperivascularlyorinto

organs/tissueswithlowcapacityforabsorption.Barbituratescanbeirritatingwhen

administeredperivascularly.

Pentobarbital sodium has the ability to cause induction excitement.

Premedication/sedationsignificantlyreducestheriskofexperiencinginduction

excitement.

Veryoccasionallyoneorafewgaspingrespirationsoccuraftercardiacarrest.Atthis

stagetheanimalisalreadyclinicallydead.

4.7Useduringpregnancy,lactationorlay

Ifeuthanasiaisnecessary,theproductcanbeusedinpregnantorlactatinganimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Whenanaggressiveanimalistoundergoeuthanasia,premedicationwithamore

easilyadministered(oral,subcutaneousorintramuscular)sedativeisrecommended.

Althoughpremedicationwithsedativesmaydelaythedesiredeffectoftheproduct

duetodecreasedcirculatoryfunctionthismaynotbeclinicallynoticeablesinceCNS

depressantdrugs(opioids,α2adrenoreceptoragonists,phenothiazinesetc)canalso

increasetheeffectofpentobarbital.

4.9 Amountstobeadministeredandadministrationroute

Adoseof140mg/kg,equivalentto0.35ml/kg,isconsideredsufficientforallindicated

routesofadministration.

Issued:December2011

AN:00665/2010

Page4of6

Theintravenousrouteofadministrationshouldbetherouteofchoiceandadequate

sedationshouldbeappliedifdeemednecessarybytheveterinarysurgeon.For

horsesandcattlepremedicationismandatory.

Whenintravenousadministrationisdifficult,andonlyfollowingdeepsedationor

anaesthesia,theproductmaybeadministeredviatheintracardiacroute.

Alternatively,forsmallanimalsonly,administrationviatheintraperitonealroute

couldbeused,butonlyfollowingappropriatesedation.

Theintravenousinjectionincompanionanimalsshouldbecarriedoutwitha

continuousinjectionrateuntilunconsciousnessoccurs.

Inhorsesandcattle,pentobarbitalshouldbeinjectedrapidly.

Thestoppershouldnotbepuncturedmorethan20times.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Notapplicable.

4.11Withdrawalperiod(s)

Adequatemeasuresshouldbetakentoensurethatcarcassesofanimalstreatedwith

thisproductandtheby-productsoftheseanimalsdonotenterthefoodchainandare

notusedforhumanoranimalconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:barbiturates

ATCvetcode:QN51AA01

5.1 Pharmacodynamicproperties

PentobarbitalsodiumisanoxybarbituratederivativeofBarbituricAcid.Barbiturates

depresstheentirecentralnervoussystembut,quantitatively,variousareasare

affecteddifferentlymakingtheproductapotenthypnoticandsedative.The

immediateeffectistheunconsciousnessofdeepanaesthesiafollowedby,athigh

doserates,rapiddepressionoftherespiratorycentre.Breathingstopsandcessation

ofheartactionquicklyfollowsleadingtorapiddeath.

5.2Pharmacokineticparticulars

Wheninjectedintothebloodstream,abarbiturateionises,thedegreedependingon

thedissociationconstantoftheagentandthepHoftheblood.Barbituratesbindwith

plasmaproteins,forminganequilibriumofboundandunbounddrugincirculating

blood.Cellpenetrationcanonlyoccurwiththeundissociatedform.

Aftercellpenetration,dissociationagainoccursandbindingofthedrugto

intracellularorganellestakesplace.

Tissuechangesduetocellularpenetrationandintracellularbindinghavenotbeen

described.Ingeneral,theeffectsontissuescanbecategorisedasdirectand

indirect.Ingeneral,theseeffectsaresubtleandlittleisknownconcerningthem.

Followingintracardiacuseunconsciousnessisalmostimmediateandcardiacarrest

followswithin10seconds.

Issued:December2011

AN:00665/2010

Page5of6

Followingintravenoususeunconsciousnessfollowsin5-10secondsafter

completionofadministration.

Deathfollows5-30secondslater.Intraperitoneally,euthanasiaisachievedin3-10

minutes(duetodepressionoftherespiratorycentre,theanimalmaybeclinically

deadpriorcardiacarrest).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Benzylalcohol(E1519)

PatentBlueV(E131)

Ethanol(96percent)

Propyleneglycol

Waterforinjections

6.2Incompatibilities

Donotmixwithothermedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

6.4.Specialprecautionsforstorage

Donotfreeze.

Storeintheoriginalpackagingtoprotectfromlight.

6.5Natureandcompositionofimmediatepackaging

100mlcolourlesstypeIIglassvialwithalightgreybromobutylrubberstopperandan

aluminiumcap.

250mlcolourlesstypeIIglassvialwithadarkgreybromobutylrubberstopperand

analuminiumcap.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Issued:December2011

AN:00665/2010

Page6of6

7. MARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Wilgenweg7

3421TVOudewater

TheNetherlands

8.MARKETINGAUTHORISATIONNUMBER

Vm19994/4016

9.DATEOFFIRSTAUTHORISATION

12December2011

10.DATEOFREVISIONOFTHETEXT

December2011

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Administrationonlybyaveterinarysurgeon.

Tobesuppliedonlyonveterinaryprescription.

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

There are no news related to this product.